Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

BACKGROUND: Cabotegravir (CAB) + rilpivirine (RPV) dosed intramuscularly monthly or every 2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 virologic suppression. Here, we report the antiretroviral therapy as long acting suppression (ATLAS)-2M study week 152 results. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Overton, Edgar T, Richmond, Gary, Rizzardini, Giuliano, Thalme, Anders, Girard, Pierre-Marie, Wong, Alexander, Porteiro, Norma, Swindells, Susan, Reynes, Jacques, Noe, Sebastian, Harrington, Conn, Español, Carlos Martín, Acuipil, Carolina, Aksar, Asma, Wang, Yuanyuan, Ford, Susan L, Crauwels, Herta, van Eygen, Veerle, Van Solingen-Ristea, Rodica, Latham, Christine L, Thiagarajah, Shanker, D’Amico, Ronald, Smith, Kimberly Y, Vandermeulen, Kati, Spreen, William R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156123/
https://www.ncbi.nlm.nih.gov/pubmed/36660819
http://dx.doi.org/10.1093/cid/ciad020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156123/
https://www.ncbi.nlm.nih.gov/pubmed/36660819
http://dx.doi.org/10.1093/cid/ciad020

Ejemplares similares